SalaryGuide
AboutPricingBlogFor Employers

Marketing jobs

1 marketing jobs

Revolution Medicines logo
5 days ago

Executive Director, US PDAC Marketing

Revolution Medicines

USA (Remote)Full time$252K/yr – $315K/yr

All marketing roles in the US with a remote work arrangement

Get alerts for this search

All marketing roles in the US with a remote work arrangement

Get alerts for this search

1 jobs
Revolution Medicines logo

Executive Director, US PDAC Marketing

Revolution Medicines

USA (Remote)

$252K/yr - $315K/yrIn-houseFull-timeDirector/executive12+ years exp.
5 days ago
Revolution Medicines logo
Revolution Medicines

Executive Director, US PDAC Marketing

USA (Remote)

$252K/yr – $315K/yrDirector/Executive12+ years expFull time

Posted 5 days ago

  • Job
  • Company
  • Salaries
  • People
  • Funding
  • Audience
  • News
  • Links

Job Summary

Own US marketing leadership for the PDAC portfolio, shaping global brand planning, launch readiness, and omnichannel education; partner with field teams, global partners, and medical affairs to drive compliant, budgeted strategy and cross-functional execution.

  • Lead US brand planning and launch readiness initiatives for the PDAC portfolio
  • Coordinate cross-functional marketing efforts with global teams, medical affairs, and field partners

Job Description

Responsibilities

  • Operate as ambassador of the company, establishing organization as trusted member of the healthcare community to all relevant stakeholders (Patients, HCPs, Payers, Policy makers, Industry peers).
  • Lead US Partnership with Global on 3 year Brand Planning for PDAC Portfolio.
  • Lead US planning with Global teams the shaping the strategic marketing plans and shared launch readiness initiatives based on deep customer insight; branding, positioning, messages, story flow.
  • Partner with the field-based Customer Marketing Team with focus on Regional Insights, and understand the needs of the top institutions, key opinion leaders, the competitor landscape, and educational programming.
  • Partner with global to shape enterprise thinking on strategic partnerships and execution plan with key business partners (diagnostic companies, EMR partners and advocacy groups).
  • Shape the international Omnichannel promotional and disease education tactics (including print and digital promotions, peer-to-peer programming, and key customer marketing initiatives) that establish value with our customers.
  • Ensure successful global partner agency and vendor relationships and workflow to support US needs.
  • Demonstrate the ability to quickly understand complex markets, disease states, competitive landscapes, and relevant market and managed care dynamics.
  • Establish a strong relationship with medical affairs, and global team to ensure optimal execution; partner with Sales Training to develop a comprehensive and effective training plan.
  • Participate in cross-functional US and global teams as marketing lead to gather input for functional activities, and ensure alignment with marketing messaging, e.g., with clinical development, medical affairs, and investor relations.

Requirements

  • Bachelor’s degree required (MBA preferred) with at least 12-15 years of progressive commercial experience in a biotechnology and/or pharmaceutical company including global strategic marketing and ideally sales.
  • Successful history of developing and executing the marketing strategy Experience in leading the launch of new products.
  • Proven experience in a smaller, rapidly growing, company.
  • Demonstrated ability to derive insights/analytics leading to the development of innovative marketing strategies.
  • Strong leadership, with the ability to work well cross-functionally and influence across an organization at all levels.
  • Excellent organizational skills and an ability to prioritize effectively to deliver results within reasonably established timelines.
  • Ability to represent Revolution Medicines well externally: strong interpersonal skills including verbal and written communication.
  • Entrepreneurial mindset, with a tolerance for ambiguity, and a passion for helping cancer patients.

Preferred

  • Targeted oncology product experience strongly preferred.
Revolution Medicines logo

Revolution Medicines

3.5 Glassdoor

We are Revolutionaries – passionate in our singular pursuit of discovering, developing and delivering innovative, targeted medicines for patients living with cancer. To deliver on our vision, we work relentlessly in pursuit of cutting-edge therapeutic approaches to some of the toughest cancers. Our current focus is on RAS-addicted cancers, which account for 30 percent of all new human cancer diagnoses.

Founded in 2014
Redwood City, California, USA
817 employees (26 in marketing)
www.revmed.com
54% recommend to a friend
64% CEO approval

Salaries

Posted range

$252K/yr – $315K/yr

Taken straight from the job posting.

See all Revolution Medicines salaries

Marketing Team

Marketing Team Size
26 (3% of company)
Median Career Experience
12 years
Median Tenure
1.7 years
Marketing Roles Posted (Last 30 Days)
6

People

Marketing Leadership

Wing Yeung
Wing Yeung
Director, Access Marketing
At the company for 1 year 5 months
Camellia Lock
Camellia Lock
Associate Director, Marketing
At the company for 1 year 9 months
Molly Klein-McDowell
Molly Klein-McDowell
Associate Marketing Director
At the company for 2 years 2 months
Kristen Eck
Kristen Eck
Senior Manager, Marketing Operations
At the company for 1 year 8 months

Funding

Total Funding
$2.3B
Last Raise
$250M
Post IPO Debt, 9 months ago

Funding History

  • Jun 2025
    Post IPO Debt • $250M
  • Dec 2024
    Post IPO Equity • $750M
  • Mar 2023
    Post IPO Equity • $323.6M

Traffic Signals

Monthly Visitors
50.4K
Traffic Source Mix
Search
39%
Direct
40.8%
Referral
7.9%
Social
11.8%
Paid
0.4%

Headcount Trend

Current headcount: ~817

Recent News

Revolution Medicines is 'within sight' of 1,000 employees and looking for a new office to fit them
Nov 17, 2025 • The Business Journals
Revolution Medicines (RVMD): Assessing Valuation After Recent 28% Monthly Share Price Surge
Nov 7, 2025 • Yahoo Finance
Revolution Medicines Posts Wider-Than-Expected Loss in Q3, Sales Nil
Nov 6, 2025 • Yahoo Finance
Does Revolution Medicines' Recent 27% Jump Reflect Its Real Value?
Nov 6, 2025 • simplywall.st
Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress
Nov 5, 2025 • GlobeNewswire
Revolution Medicines Inc (RVMD) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ...
Nov 5, 2025 • Yahoo Finance
Revolution Medicines to Participate in November 2025 Investor Conferences
Nov 4, 2025 • GlobeNewswire
Revolution Medicines Inc (RVMD) Q3 2025: Everything You Need To Know Ahead Of Earnings
Nov 4, 2025 • Yahoo Finance
Revolution Medicines a new outperform at RBC on RAS(ON) inhibitors for cancers
Nov 3, 2025 • Seeking Alpha
Revolution Medicines’ RAS(ON) Multi-Selective Inhibitor
Oct 27, 2025 • GlobeNewswire
Revolution Medicines stock rises after FDA grants Orphan Drug Designation
Oct 27, 2025 • Investing.com
Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA
Oct 24, 2025 • The Cancer Letter
Triple meeting 2025 – Revolution hints at post-KRAS promise | ApexOnco - Clinical Trials news and analysis
Oct 23, 2025 • Oncology Pipeline
Revolution Medicines Snags One of First New FDA Vouchers to Speed Review
Oct 22, 2025 • Inside Precision Medicine
Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor
Oct 22, 2025 • Yahoo Finance
Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor
Oct 22, 2025 • GlobeNewswire
Mizuho initiates Revolution Medicines stock with Outperform rating
Oct 20, 2025 • Investing.com
Revolution Medicines: A Big Deal, But With A Big Price Tag (NASDAQ:RVMD)
Oct 20, 2025 • Seeking Alpha
Revolution Medicines (RVMD): Examining Valuation After Recent Stock Momentum and Long-Term Gains
Oct 20, 2025 • Yahoo Finance
Jim Cramer Says Revolution Medicines “Is a Speculative Situation”
Oct 19, 2025 • Yahoo Finance
Revolution Medicines Receives FDA Voucher for Daraxonrasib Under National Priority Voucher Pilot Program
Oct 17, 2025 • Quiver Quantitative
Revolution Medicines stock surges after FDA grants priority voucher
Oct 17, 2025 • Investing.com
Revolution Medicines Awarded Voucher for Daraxonrasib
Oct 17, 2025 • GlobeNewswire
Revolution Medicines Stock Gains Momentum: Here’s Why
Oct 8, 2025 • TipRanks
Revolution Medicines’ SWOT analysis: RAS inhibitor stock poised for growth amid fierce competition
Oct 8, 2025 • Investing.com
Did Leadership Moves Just Shift Revolution Medicines' (RVMD) Investment Narrative Ahead of Key Launches?
Oct 7, 2025 • Yahoo Finance
Assessing Revolution Medicines After Recent Cancer Breakthrough and 15% Monthly Rally
Oct 6, 2025 • Yahoo Finance
Revolution Medicines, Inc. (RVMD) Insider Sells Shares
Oct 2, 2025 • Yahoo Finance
Revolution Medicines Shows Improved Relative Strength; Still Shy Of Benchmark
Sep 30, 2025 • Investor's Business Daily
Revolution Medicines appoints new chief development officer
Sep 29, 2025 • Investing.com
Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer
Sep 29, 2025 • Yahoo Finance
Former Mirati and Genentech Executive Alan Sandler Joins Revolution Medicines to Lead RAS Cancer Programs
Sep 29, 2025 • Stock Titan
Revolution Medicines Stock Soars Amid Strategic Moves
Sep 29, 2025 • TipRanks
Revolution Medicines appoints Alan Sandler as CDO
Sep 29, 2025 • thefly.com
Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer
Sep 29, 2025 • Revolution Medicines, Inc.
Cislini Jeff, general counsel at Revolution Medicines, sells $79,623 in stock
Sep 26, 2025 • Investing.com
Revolution Medicines price target raised by $1 at JPMorgan, here's why
Sep 25, 2025 • thefly.com
Revolution Medicines Insider Sold Shares Worth $614,558, According to a Recent SEC Filing
Sep 18, 2025 • MarketScreener
Revolution Medicines Insider Sold Shares Worth $5,557,754, According to a Recent SEC Filing
Sep 16, 2025 • MarketScreener
The week in pharma: action, reaction and insight – week to September 12
Sep 14, 2025 • Pharma Letter
REVOLUTION Medicines
Sep 12, 2025 • Pharma Letter
Revolution advances daraxonrasib to Phase III in pancreatic cancer
Sep 12, 2025 • Pharma Letter
Revolution Medicines: Shares Soar On Pancreatic Cancer Study Win - I'm Sold (NASDAQ:RVMD)
Sep 11, 2025 • Seeking Alpha
Revolution’s daraxonrasib moves to Phase III after PDAC hat-trick
Sep 11, 2025 • Clinical Trials Arena
Revolution Medicines’ Surging Potential: What’s Happening?
Sep 11, 2025 • StocksToTrade
Revolution Medicines (RVMD) Announces Promising Phase 1 Daraxonrasib Clinical Trial Results
Sep 11, 2025 • Yahoo Finance
Analysts Raise Price Targets Following Strong Data From Revolution Medicines' Pancreatic Cancer Drug
Sep 11, 2025 • Benzinga.com
Revolution takes early stage cues for a phase III in pancreatic cancer
Sep 11, 2025 • BioWorld Financial Watch
Revolution Medicines rises 14.2%
Sep 11, 2025 • thefly.com
Transcript : Revolution Medicines, Inc. - Special Call
Sep 11, 2025 • MarketScreener
Revolution Medicines announces results from daraxonrasib Phase 1 trials
Sep 11, 2025 • thefly.com
Revolution Medicines rises on daraxonrasib data that supports phase 3 program
Sep 10, 2025 • Seeking Alpha
Revolution Medicines Reports Promising Phase 1 Study Results
Sep 10, 2025 • TipRanks
Revolution Medicines Reports Promising Long-term Data for Daraxonrasib in Metastatic Pancreatic Cancer and Announces Phase 3 Trial Plans
Sep 10, 2025 • Quiver Quantitative
Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma
Sep 10, 2025 • GlobeNewswire
Revolution Medicines (RVMD): Assessing Valuation After Truist Highlights Potential of RAS-mutant Cancer Pipeline
Sep 9, 2025 • Yahoo Finance
Revolution Medicines (RVMD) Is Up 6.7% After Truist’s Bullish Initiation Is the Pipeline Rethink Underway?
Sep 8, 2025 • Yahoo Finance
Revolution Medicines stock initiated with Buy rating at Truist Securities
Sep 5, 2025 • Investing.com
Oppenheimer Reaffirms Outperform on Revolution Medicines (RVMD) Amid RAS Therapy Progress
Sep 1, 2025 • Yahoo Finance
Royalty Pharma plc (RPRX) Strikes $2B Partnership with Revolution Medicines
Aug 29, 2025 • Yahoo Finance
This Parker-Hannifin Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Aug 15, 2025 • Benzinga.com
Revolution Medicines Receives FDA Breakthrough Therapy Designation for Elironrasib for Lung Cancer
Aug 13, 2025 • Yahoo Finance
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025
Aug 12, 2025 • BioSpace
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025
Aug 11, 2025 • MarketScreener
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025
Aug 11, 2025 • Business Wire
Revolution Medicines August 2025 slides: advancing RAS inhibitor pipeline with promising data
Aug 7, 2025 • Investing.com
Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress
Aug 6, 2025 • Yahoo Finance
Royalty Pharma Reports Second Quarter 2025 Results
Aug 6, 2025 • Royalty Pharma plc
Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress
Aug 6, 2025 • Revolution Medicines, Inc.
Revolution Medicines Q2 Loss Widens
Aug 6, 2025 • MarketScreener
Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025
Jul 30, 2025 • GlobeNewswire
Iambic Therapeutics and Revolution Medicines Announce AI-Driven Oncology Collaboration
Jul 30, 2025 • globallegalchronicle.com
Wall Street Analysts Believe Revolution Medicines (RVMD) Could Rally 90.58%: Here's is How to Trade
Jul 28, 2025 • Nasdaq
Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor
Jul 24, 2025 • GlobeNewswire
iOnctura Appoints Dr. Neil Gallagher and Anthony Mancini To Board
Jul 24, 2025 • citybiz
iOnctura Strengthens Medical and Commercialization Expertise with Two Non-Executive Board Appointments
Jul 24, 2025 • PR Newswire UK
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib
Jul 23, 2025 • Yahoo Finance
Revolution Medicines announces FDA BTD to elironrasib
Jul 23, 2025 • thefly.com
Revolution Medicines (RVMD) Gets Initiated With a New Buy Rating at Goldman Sachs
Jul 16, 2025 • Yahoo Finance
Revolution Medicines Fair Value call captures 40% downside in biotech stock
Jul 14, 2025 • Investing.com
Wilson Sonsini Advises Iambic Therapeutics on Technology and Research Collaboration with Revolution Medicines
Jul 10, 2025 • Wilson Sonsini
Revolution lines up Iambic's AI platform in discovery collab worth up to $25M
Jul 9, 2025 • Fierce Biotech
Iambic and Revolution Medicines Partner on AI Cancer Drug Discovery
Jul 9, 2025 • Genetic Engineering and Biotechnology News
Revolution Medicines and Iambic Announce Technology and
Jul 9, 2025 • GlobeNewswire
Revolution Medicines’ Daraxonrasib Granted FDA Breakthrough Therapy Designation for Pancreatic Cancer with KRAS G12 Mutations
Jul 8, 2025 • Yahoo Finance
Revolution Medicines, Summit Therapeutics Partner on RAS Inhibitor/Ivonescimab Combinations for Solid Tumors
Jul 6, 2025 • Yahoo Finance
Oppenheimer Reaffirms Outperform on Revolution Medicines, Cites PDAC and NSCLC Trial Progress
Jul 2, 2025 • Yahoo Finance
Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors
Jun 30, 2025 • GlobeNewswire
Revolution Medicines, Summit Therapeutics Enter Clinical Collaboration
Jun 30, 2025 • Nasdaq
Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors
Jun 30, 2025 • Business Wire
Revolution Medicines partners Royalty Pharma on $2bn funding
Jun 25, 2025 • Pharmaceutical Technology
Latham & Watkins Advises Revolution Medicines on US$2 Billion Growth Financing With Royalty Pharma
Jun 24, 2025 • Latham & Watkins LLP
Revolution Medicines secures $2 billion funding deal with Royalty Pharma
Jun 24, 2025 • Investing.com
Revolution Medicines Secures $2 Billion Funding Agreement
Jun 24, 2025 • TipRanks
Revolution's RAS-driven ambitions get $2B boost from Royalty Pharma
Jun 24, 2025 • FirstWord Pharma
Revolution Establishes Endless Cash Runway With $2B Royalty Pharma Deal
Jun 24, 2025 • BioSpace
Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers
Jun 24, 2025 • GlobeNewswire
Royalty signs off on $2B to bankroll Revolution's RAS cancer drug's road to regulators
Jun 24, 2025 • Fierce Biotech
Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug
Jun 24, 2025 • Reuters
Revolution Medicines Partners Royalty Pharma On $2 Bln Flexible Funding
Jun 24, 2025 • Nasdaq

Links

www.revmed.comLinkedInCrunchbase